Banco Bilbao Vizcaya Argentaria S.A. Has $10.76 Million Stock Holdings in ResMed Inc. (NYSE:RMD)

Banco Bilbao Vizcaya Argentaria S.A. lifted its holdings in ResMed Inc. (NYSE:RMD - Free Report) by 2.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 47,051 shares of the medical equipment provider's stock after purchasing an additional 1,171 shares during the period. Banco Bilbao Vizcaya Argentaria S.A.'s holdings in ResMed were worth $10,760,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Vanguard Group Inc. lifted its position in shares of ResMed by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 18,173,462 shares of the medical equipment provider's stock worth $4,156,089,000 after buying an additional 160,590 shares during the last quarter. Geode Capital Management LLC lifted its holdings in ResMed by 2.2% in the 4th quarter. Geode Capital Management LLC now owns 3,944,084 shares of the medical equipment provider's stock worth $899,860,000 after purchasing an additional 85,270 shares during the last quarter. Invesco Ltd. boosted its position in ResMed by 32.2% during the fourth quarter. Invesco Ltd. now owns 2,325,009 shares of the medical equipment provider's stock worth $531,706,000 after purchasing an additional 566,046 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in ResMed by 3.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 957,020 shares of the medical equipment provider's stock valued at $218,861,000 after purchasing an additional 32,973 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its position in shares of ResMed by 9.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 742,412 shares of the medical equipment provider's stock valued at $169,789,000 after purchasing an additional 65,999 shares during the period. 54.98% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

RMD has been the topic of a number of research analyst reports. Needham & Company LLC reiterated a "hold" rating on shares of ResMed in a research note on Friday, January 31st. Morgan Stanley initiated coverage on ResMed in a research report on Wednesday, March 19th. They issued an "overweight" rating and a $280.00 price target on the stock. Citigroup raised ResMed from a "neutral" rating to a "buy" rating in a research report on Wednesday, March 5th. StockNews.com lowered ResMed from a "buy" rating to a "hold" rating in a report on Thursday. Finally, The Goldman Sachs Group assumed coverage on ResMed in a report on Thursday, January 16th. They set a "buy" rating for the company. One analyst has rated the stock with a sell rating, six have given a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $258.83.

Insider Buying and Selling at ResMed

In other news, insider Kaushik Ghoshal sold 9,113 shares of the company's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $235.40, for a total value of $2,145,200.20. Following the sale, the insider now owns 9,725 shares of the company's stock, valued at approximately $2,289,265. This represents a 48.38 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Peter C. Farrell sold 2,000 shares of ResMed stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $242.11, for a total transaction of $484,220.00. Following the transaction, the director now directly owns 77,218 shares of the company's stock, valued at $18,695,249.98. This represents a 2.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 49,013 shares of company stock worth $11,298,816 over the last three months. Company insiders own 0.71% of the company's stock.

ResMed Price Performance

Shares of RMD stock traded down $1.82 during mid-day trading on Monday, reaching $234.06. The company's stock had a trading volume of 1,117,896 shares, compared to its average volume of 1,017,721. The firm's 50-day moving average is $221.92 and its two-hundred day moving average is $234.00. The company has a market cap of $34.38 billion, a P/E ratio of 27.63, a PEG ratio of 1.53 and a beta of 0.75. ResMed Inc. has a 1-year low of $179.42 and a 1-year high of $263.05. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.29 and a current ratio of 3.33.

ResMed (NYSE:RMD - Get Free Report) last announced its quarterly earnings results on Wednesday, April 23rd. The medical equipment provider reported $2.37 EPS for the quarter, topping analysts' consensus estimates of $2.36 by $0.01. The firm had revenue of $1.29 billion during the quarter, compared to analysts' expectations of $1.28 billion. ResMed had a net margin of 25.34% and a return on equity of 26.17%. The company's revenue for the quarter was up 7.9% compared to the same quarter last year. During the same quarter last year, the company earned $2.13 earnings per share. On average, research analysts predict that ResMed Inc. will post 9.47 earnings per share for the current year.

ResMed Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 12th. Investors of record on Thursday, May 8th will be paid a $0.53 dividend. This represents a $2.12 annualized dividend and a yield of 0.91%. The ex-dividend date is Thursday, May 8th. ResMed's dividend payout ratio is 23.79%.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.